Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease
Gut-Lung Axis Microbiome in Clinically Stable COPD
Airway and gut dysbiosis have been reported in Chronic Obstructive Pulmonary Disease (COPD); however, their relationship and association with clinical features remain poorly understood.
We aimed to characterise the lung and gut microbiome in patients with stable COPD and controls.
Airway and Gut Microbiome Findings in COPD
We found that the microbiome in airway and stool samples was highly dissimilar both in patients and controls, with 0.37% of this diversity associated to COPD.
The microbiome taxa associated with COPD in OP swabs and sputum were highly similar, but different from BALF, suggesting that OP swabs can be a surrogate sample of sputum.
Clinical Relevance of the Gut-Lung Axis Microbiome
The gut and lung microbiomes in patients with COPD are distinct, but both clinically relevant as both present bacterial associations with airflow limitation, exacerbation history, and ICS use.
Authors
Julieta Viglino, Lidia Perea, Marian Garcia-Nuñez, Ana Rodrigo-Troyano, Alfons Torrego, Marisol Domínguez-Alvarez, Judith Villar, Xènia Carrizosa, Sara Quero, Toni Gabaldon, Jesse R Willis, Ester Saus, Joaquim Gea, Salud Santos, Paula Camps, Alvar Agustí, Eduard Monso, Oriol Sibila, Rosa Faner.
Read more details at
Fecha de publicación
Publication date (Epub): 2 January 2026.
Categorías asociadas al artículo
Noticias relacionadas
Clinical impact of mucus plugs in bronchiectasis
Mucus plugs in bronchiectasis are associated with worse respiratory symptoms and chronic Pseudomonas aeruginosa infection in a study of 133 adults.
Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD
AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC-16: implications for lung development and COPD across the lifespan
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Concavity of the maximal expiratory flow–volume curve, and incidence of COPD and respiratory symptoms: a population-based cohort study
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Body Mass Index-related genetic factors and COPD imaging phenotypes
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
Imagen desarrollada con ChatGPT